Jasper Therapeutics Stock Fundamentals
| JSPR Stock | USD 22.47 0.16 0.72% |
Jasper Therapeutics fundamentals help investors to digest information that contributes to Jasper Therapeutics' financial success or failures. It also enables traders to predict the movement of Jasper Stock. The fundamental analysis module provides a way to measure Jasper Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jasper Therapeutics stock.
As of 12/11/2024, Depreciation And Amortization is likely to grow to about 1.2 M, while Interest Expense is likely to drop slightly above 8.4 M. Jasper | Select Account or Indicator |
Jasper Therapeutics Company Return On Asset Analysis
Jasper Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Jasper Therapeutics Return On Asset | -0.41 |
Most of Jasper Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jasper Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Jasper Total Assets
Total Assets |
|
Based on the latest financial disclosure, Jasper Therapeutics has a Return On Asset of -0.4092. This is 95.32% lower than that of the Biotechnology sector and 98.27% lower than that of the Health Care industry. The return on asset for all United States stocks is 192.29% higher than that of the company.
Jasper Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Jasper Therapeutics's current stock value. Our valuation model uses many indicators to compare Jasper Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Jasper Therapeutics competition to find correlations between indicators driving Jasper Therapeutics's intrinsic value. More Info.Jasper Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Jasper Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Jasper Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Jasper Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jasper Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jasper Therapeutics could also be used in its relative valuation, which is a method of valuing Jasper Therapeutics by comparing valuation metrics of similar companies.Jasper Therapeutics is currently under evaluation in return on asset category among its peers.
Jasper Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Jasper Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Jasper Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Jasper Fundamentals
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 245.6 M | ||||
| Shares Outstanding | 15 M | ||||
| Shares Owned By Insiders | 4.98 % | ||||
| Shares Owned By Institutions | 95.02 % | ||||
| Number Of Shares Shorted | 1.94 M | ||||
| Price To Book | 4.02 X | ||||
| EBITDA | (64.98 M) | ||||
| Net Income | (64.47 M) | ||||
| Cash And Equivalents | 60.81 M | ||||
| Cash Per Share | 1.60 X | ||||
| Total Debt | 2.79 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 9.56 X | ||||
| Book Value Per Share | 5.58 X | ||||
| Cash Flow From Operations | (52.07 M) | ||||
| Short Ratio | 9.32 X | ||||
| Earnings Per Share | (4.75) X | ||||
| Target Price | 68.78 | ||||
| Number Of Employees | 45 | ||||
| Beta | 2.2 | ||||
| Market Capitalization | 336.03 M | ||||
| Total Asset | 94.89 M | ||||
| Retained Earnings | (169.6 M) | ||||
| Working Capital | 76.56 M | ||||
| Net Asset | 94.89 M |
About Jasper Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jasper Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jasper Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jasper Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 2.5 M | 2.2 M | |
| Cost Of Revenue | 1.1 M | 826.4 K |
Pair Trading with Jasper Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jasper Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jasper Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Jasper Stock
| 0.68 | IMAB | I Mab | PairCorr |
| 0.48 | GNFT | Genfit | PairCorr |
| 0.45 | LLY | Eli Lilly | PairCorr |
| 0.44 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.4 | FLGC | Flora Growth Corp | PairCorr |
The ability to find closely correlated positions to Jasper Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jasper Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jasper Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jasper Therapeutics to buy it.
The correlation of Jasper Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jasper Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jasper Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Jasper Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.